These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33797985)

  • 1. Open-label pilot study of lisdexamfetamine for cocaine use disorder.
    Mariani JJ; Choi CJ; Pavlicova M; Mahony AL; Brooks DJ; Grabowski J; Levin FR
    Am J Drug Alcohol Abuse; 2021 May; 47(3):402-409. PubMed ID: 33797985
    [No Abstract]   [Full Text] [Related]  

  • 2. Pilot study of the effects of lisdexamfetamine on cocaine use: A randomized, double-blind, placebo-controlled trial.
    Mooney ME; Herin DV; Specker S; Babb D; Levin FR; Grabowski J
    Drug Alcohol Depend; 2015 Aug; 153():94-103. PubMed ID: 26116930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial.
    Hudson JI; McElroy SL; Ferreira-Cornwell MC; Radewonuk J; Gasior M
    JAMA Psychiatry; 2017 Sep; 74(9):903-910. PubMed ID: 28700805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth and Puberty in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Banaschewski T; Johnson M; Nagy P; Otero IH; Soutullo CA; Yan B; Zuddas A; Coghill DR
    CNS Drugs; 2018 May; 32(5):455-467. PubMed ID: 29790103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lisdexamfetamine Dimesylate: A Review in Paediatric ADHD.
    Frampton JE
    Drugs; 2018 Jul; 78(10):1025-1036. PubMed ID: 29923015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 12-Month Open-Label Extension Study of the Safety and Tolerability of Lisdexamfetamine Dimesylate for Major Depressive Disorder in Adults.
    Richards C; Iosifescu DV; Mago R; Sarkis E; Geibel B; Dauphin M; McIntyre RS; Weisler R; Brawman-Mintzer O; Gu J; Madhoo M
    J Clin Psychopharmacol; 2018 Aug; 38(4):336-343. PubMed ID: 29912786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.
    Brams M; Weisler R; Findling RL; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
    J Clin Psychiatry; 2012 Jul; 73(7):977-83. PubMed ID: 22780921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive Function of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate.
    Coghill DR; Banaschewski T; Bliss C; Robertson B; Zuddas A
    CNS Drugs; 2018 Jan; 32(1):85-95. PubMed ID: 29383572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of open-label lisdexamfetamine dimesylate on self-reported quality of life in adults with ADHD.
    Brams M; Giblin J; Gasior M; Gao J; Wigal T
    Postgrad Med; 2011 May; 123(3):99-108. PubMed ID: 21566420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
    Findling RL; Cutler AJ; Saylor K; Gasior M; Hamdani M; Ferreira-Cornwell MC; Childress AC
    J Child Adolesc Psychopharmacol; 2013 Feb; 23(1):11-21. PubMed ID: 23410138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study protocol: a dose-escalating, phase-2 study of oral lisdexamfetamine in adults with methamphetamine dependence.
    Ezard N; Dunlop A; Clifford B; Bruno R; Carr A; Bissaker A; Lintzeris N
    BMC Psychiatry; 2016 Dec; 16(1):428. PubMed ID: 27905916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lisdexamfetamine dimesylate in binge eating disorder: a placebo controlled trial.
    Guerdjikova AI; Mori N; Blom TJ; Keck PE; Williams SL; Welge JA; McElroy SL
    Hum Psychopharmacol; 2016 Sep; 31(5):382-91. PubMed ID: 27650406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
    Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA
    J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder.
    Childress AC; Findling RL; Wu J; Kollins SH; Wang Y; Martin P; Robertson B
    J Child Adolesc Psychopharmacol; 2020 Apr; 30(3):128-136. PubMed ID: 32233956
    [No Abstract]   [Full Text] [Related]  

  • 16. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
    Adler LA; Goodman DW; Kollins SH; Weisler RH; Krishnan S; Zhang Y; Biederman J;
    J Clin Psychiatry; 2008 Sep; 69(9):1364-73. PubMed ID: 19012818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lisdexamfetamine: A Review in Binge Eating Disorder.
    Heo YA; Duggan ST
    CNS Drugs; 2017 Nov; 31(11):1015-1022. PubMed ID: 29134566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe.
    Coghill DR; Banaschewski T; Nagy P; Otero IH; Soutullo C; Yan B; Caballero B; Zuddas A
    CNS Drugs; 2017 Jul; 31(7):625-638. PubMed ID: 28667569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults.
    Castells X; Blanco-Silvente L; Cunill R
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD007813. PubMed ID: 30091808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Trial of Lisdexamfetamine Dimesylate in Adults With Binge Eating Disorder.
    Gasior M; Hudson J; Quintero J; Ferreira-Cornwell MC; Radewonuk J; McElroy SL
    J Clin Psychopharmacol; 2017 Jun; 37(3):315-322. PubMed ID: 28383364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.